Volume 9, Number 8—August 2003
Research
Community-Acquired Methicillin-Resistant Staphylococcus aureus Carrying Panton-Valentine Leukocidin Genes: Worldwide Emergence
François Vandenesch*, Timothy Naimi†, Mark C. Enright‡, Gerard Lina*, Graeme R. Nimmo§, Helen Heffernan¶, Nadia Liassine#, Michèle Bes*, Timothy Greenland**, Marie-Elisabeth Reverdy*, and Jerome Etienne*
Table 2
MIC50 and MIC90 of staphylococcal antibiotics against community-acquired methicillin resistant Staphylococcus aureus (CA-MRSA) from Europe (46 isolates), United States (22 isolates), and Oceania (13 isolates)
| Antibiotics | Isolates from Europe |
Isolates from United States and Oceania |
||||
|---|---|---|---|---|---|---|
| MIC50 mg/L | MIC90 mg/L | Range mg/L | MIC50 mg/L | MIC90 mg/L | Range mg/L | |
| Benzyl-penicillin | 8 | 8 | 0.25–8 | 16 | 16 | 4–32 |
| Oxacillin | 16 | 32 | 4–64 | 64 | 64 | 16–64 |
| Kanamycin | 128 | 128 | 128 | 2 | 2 | 2 |
| Tobramycin | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 |
| Gentamicin | 1 | 1 | 0.5–1 | 1 | 1 | 0.5–2 |
| Erythromycin | 0.5 | 128 | 0.25–128 | 0.25 | 0.5 | 0.25–128 |
| Lincomycin | 0.5 | 0.5 | 0.5–32 | 0.5 | 0.5 | 0.25–32 |
| Pristinamycin | 0.5 | 0.5 | 0.12–1 | 0.5 | 0.5 | 0.12–1 |
| Tetracycline | 16 | 16 | 0.25–16 | 0.25 | 0.25 | 0.25–32 |
| Minocycline | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 |
| Chloramphenicol | 4 | 4 | 4–8 | 4 | 8 | 4–8 |
| Ofloxacin | 0.12 | 0.12 | 0.12–0.5 | 0.12 | 0.25 | 0.12–1 |
| Fusidic acid | 4 | 4 | 0.12–64 | 0.12 | 0.12 | 0.12 |
| Vancomycin | 0.5 | 0;5 | 0.5–1 | 0.5 | 0;5 | 0.5–1 |
| Teicoplanin | 0.5 | 0.5 | 0.25–0.5 | 0.25 | 0.5 | 0.25–0.5 |
| Fosfomycin | 2 | 2 | 0.25–2 | 1 | 2 | 0.25–2 |
| Rifampin | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 |
| Co-trimoxazole | 0.5/9.5 | 0.5/9.5 | 0.5/9.5 | 0.5/9.5 | 0.5/9.5 | 0.5/9.5 |
| Linezolid | 0.5 | 1 | 0.25–1 | 0.5 | 1 | 0.25–1 |
| Mupirocin | 0.12 | 0.12 | 0.12–8 | 0.12 | 0.12 | 0.12 |
Page created: December 22, 2010
Page updated: December 22, 2010
Page reviewed: December 22, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.